Welcome to Multibagg AI
Log in to access personalized features
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
40.50 | 45 Cr | 17.26 | 1.30 | 0.00 | 6.41 | 11.62 | 7.69 | ||
0.50 | 42 Cr | 17.04 | 0.43 | 0.00 | 1.73 | 1.73 | 2.51 | ||
74.70 | 42 Cr | 211.05 | 3.62 | 0.00 | 2.02 | 2.86 | 1.62 | ||
59.85 | 41 Cr | -2.51 | 2.20 | 0.00 | -120.81 | -79.20 | -58.56 | ||
5.88 | 41 Cr | -1023.00 | 1.60 | 0.00 | -0.17 | 2.30 | -0.05 | ||
74.49 | 39 Cr | -8.71 | 2.11 | 0.00 | -18.29 | -20.39 | -26.80 | ||
40.38 | 39 Cr | 81.25 | 2.56 | 0.00 | -0.51 | -0.28 | 3.04 | ||
| Median: 7 Co. | — | 40.50 | 41 Cr | 17.04 | 2.11 | 0.00 | -0.17 | 1.73 | 1.62 |
Biogen Pharmachem Industries Ltd (BIOGEN) is currently trading at 0.49 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Biogen Pharmachem Industries Ltd is a versatile company with operations in stock broking, trading commodities like agro-based and precious metals, and generating wind power. The company initially started its operations focusing on trading activities, particularly in present and future markets for commodities and shares. Recently, the company has made a strategic pivot towards becoming a pharmaceutical entity, as of March 2021, indicative of a shift in business priorities. Biogen has a legacy of exploration in high-value trading markets, including a notable interest in precious metals such as gold, silver, and diamonds. Alongside its trading operations, the company has diversified into renewable energy by operating wind power generation plants.
Over the past 52 weeks, Biogen Pharmachem Industries Ltd has traded between a low of ₹0.48 and a high of ₹1.08. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Biogen Pharmachem Industries Ltd has a market capitalization of approximately 42.42. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Biogen Pharmachem Industries Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 17.04 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 42.42 Cr, Biogen Pharmachem Industries Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Biogen Pharmachem Industries Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Biogen Pharmachem Industries Ltd is 17.04. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
It is a strategic initiative with a ₹10,000 crore outlay over five years to develop India as a global biopharma manufacturing hub, focusing on biologics, research, and building a supportive ecosystem.
Bonus Issue Approval
Members approved via postal ballot (23 Mar 2026) an increase in authorised share capital and consequent amendment to the Memorandum of Association to enable issuance of bonus shares.
Postal Ballot Result
Biogen Pharmachem shareholders, via postal ballot, approved a 1:6 bonus issue, increase in authorised share capital and appointment of M/s Goenka Mehta & Associates as statutory auditors; 26.41% turnout with 99.99% votes in favour.
Postal Ballot Results
Biogen Pharmachem reports postal ballot approvals: shareholders approved bonus issue (1:6), increase in authorised share capital (MoA alteration) and appointment of M/s Goenka Mehta & Associates as statutory auditors; turnout 26.41%, 99.99% votes in favour.
Postal Ballot Result
Biogen Pharmachem announced postal ballot results: shareholders approved a bonus issue of 1:6, increase in authorised share capital (MoA amendment) and appointment of M/s Goenka Mehta & Associates as statutory auditors; turnout ~26.41% and approvals ~99.99%.
Postal Ballot Results
Postal ballot results (27 Apr 2026): shareholders approved a bonus issue in the ratio 1:6, increase in authorised share capital and appointment of M/s Goenka Mehta & Associates as statutory auditors; bonus resolution passed with ~26.41% turnout and 99.99% votes in favour.
Bearish
3
Neutral
7
Bullish
4
Bearish
25
Neutral
15
Bullish
6
Bearish
22
Neutral
8
Bullish
2
Biogen Pharmachem Industries Ltd is a versatile company with operations in stock broking, trading commodities like agro-based and precious metals, and generating wind power.
The company initially started its operations focusing on trading activities, particularly in present and future markets for commodities and shares.
Recently, the company has made a strategic pivot towards becoming a pharmaceutical entity, as of March 2021, indicative of a shift in business priorities.
Biogen has a legacy of exploration in high-value trading markets, including a notable interest in precious metals such as gold, silver, and diamonds.
Alongside its trading operations, the company has diversified into renewable energy by operating wind power generation plants.
Finance
Other Financial Services
42 Cr
Low Risk
17.0
19.1
-0.0
0.4
1.08
0.48
Sales CAGR
Profit CAGR
ROE
ROCE
